JP Morgan Healthcare Conference, January 2019; Optio Biopharma Solutions conducts neurodegenerative rare disease asset valuation due diligence and other activities

JPM, January 2019, San Francisco. In addition to attending JPM meetings with a focus on rare disease, Optio conducted asset valuation work on behalf of a client. Discussions with a potential out-licensing partner were held to reach an understanding on market assumptions. Optio provided due diligence through interviews with relevant thought leaders combined with expert opinion on valuation and commercial risk.